Essential fatty acid supplement
Omega-3 Fish Oil
The Vascepa label, for icosapent ethyl, a prescription ethyl ester of EPA, gives EPA a plasma elimination half-life of approximately 89 hours; the app lists 48 hours for omega-3 fish oil.1
Omega-3 Fish Oil after one dose: 50% at ~48 h, 25% at 96 h, 12.5% at 144 h.
Drawn from the half-life in the app's model, ~48 h. The model's figures
- Compound
- Omega-3 Fish Oil
- Symbol
- O3
- Family
- Supplements
- Parts
- 14
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
The app lists omega-3 fish oil as a supplement in the essential fatty acid sub-category, taken by mouth at a typical 2 to 4 g/day. Two US prescription products carry labels read for this entry: Vascepa, an ethyl ester of eicosapentaenoic acid (EPA), and Lovaza, a combination of ethyl esters principally of EPA and docosahexaenoic acid (DHA).1,2 The Vascepa label lists use as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in adults with elevated triglycerides and established cardiovascular disease or diabetes with 2 or more additional risk factors, and as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridemia.1 The Lovaza label lists one use, as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridemia (500 mg/dL or higher).2 The large outcome trials below tested a prescription EPA ethyl ester (REDUCE-IT), a carboxylic acid formulation of EPA and DHA (STRENGTH), a 1 g/day fish-oil capsule (VITAL) and 1-g capsules of n-3 fatty acids (ASCEND), so their results belong to those products and doses.3,4,5,6 The app grades the evidence strong; the trials were funded by Amarin Pharma (REDUCE-IT), AstraZeneca (STRENGTH), the National Institutes of Health and others (VITAL) and the British Heart Foundation and others (ASCEND).3,4,5,6
How it works
Sources in this part
The Vascepa label says the mechanisms contributing to reduction of cardiovascular events with icosapent ethyl are "not completely understood but are likely multi-factorial".1 It notes increased EPA in carotid plaque specimens and a higher circulating EPA/arachidonic acid ratio after EPA treatment, that EPA inhibits platelet aggregation "under some ex vivo conditions", and that "the direct clinical meaning of individual findings is not clear".1 The Lovaza label also states that its mechanism of action "is not completely understood" and lists potential mechanisms: inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~48 h
- Bioavailability
- 95%
- Typical dose
- 2–4 g/day
- Route
- Oral
- Time to peak
- ~6 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~48 h (2 days) | EPA elimination half-life of approximately 89 hours on the Vascepa label; EPA half-life in plasma phospholipids 1.63 to 2.31 days (mean 1.97 days) and in cholesteryl esters a mean of 3.27 days in 5 healthy volunteers; plasma 13C-DHA half-life 4.5 days at baseline and 3.0 days on a fish oil supplement in 34 older adults1,7,8 |
| Bioavailability | 95% | The Vascepa and Lovaza labels describe absorption (EPA is absorbed in the small intestine and enters the circulation mainly via the thoracic duct lymphatic system) but give no absolute bioavailability percentage1,2 |
| Time to peak | ~6 h | Peak plasma concentrations of EPA reached approximately 5 hours after oral doses of Vascepa1 |
| Model | One-compartment | Washout of EPA and DHA from triacylglycerols seemed to follow a bi-exponential pattern in 3 of 5 volunteers7 |
The app's 48 hours is close to the 1.97-day (about 47-hour) mean that Zuijdgeest-van Leeuwen and colleagues (British Journal of Nutrition, 1999) reported for EPA in plasma phospholipids, and below the 89 hours on the Vascepa label for plasma EPA.7,1 The Zuijdgeest-van Leeuwen authors describe their half-life data as "preliminary information", and the study had 5 volunteers given 6.0 g EPA and 5.3 g DHA per day, above the app's 2 to 4 g/day.7 Plourde and colleagues (American Journal of Clinical Nutrition, 2014) traced a single 40 mg dose of labelled DHA in 34 older adults and found the plasma half-life shorter on a fish oil supplement than at baseline.8 The Vascepa label says the majority of circulating EPA is incorporated in phospholipids, triglycerides and cholesteryl esters, that EPA is mainly metabolized in the liver by beta-oxidation, and that the drug does not undergo renal excretion.1 The Lovaza label reports dose-dependent increases in serum phospholipid EPA content, with DHA increases that were "less marked and not dose-dependent".2
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: twice daily (Vascepa label, 4 g/day as two doses)1, once daily (Lovaza label allows a single 4 g dose)2.
An illustration from a pharmacokinetic model using a half-life of 48 hours (2 days). It is not a measured level or a suggested dose.
Human studies
Large outcome trials of omega-3 products have not given one answer: REDUCE-IT reported fewer cardiovascular events with icosapent ethyl, while STRENGTH, VITAL and ASCEND reported no significant difference in their primary outcomes.3,4,5,6
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Bhatt and colleagues, REDUCE-IT, New England Journal of Medicine 20193 | Multicenter, randomized, double-blind, placebo-controlled; funded by Amarin Pharma3 | 8179 statin-treated patients with established cardiovascular disease, or diabetes and other risk factors, and fasting triglycerides of 135 to 499 mg per deciliter3 | Icosapent ethyl 2 g twice daily (4 g/day) or placebo; median follow-up 4.9 years3 | Primary composite in 17.2% against 22.0% (hazard ratio 0.75, 95% CI 0.68 to 0.83); hospitalized for atrial fibrillation or flutter 3.1% against 2.1% (P=0.004); serious bleeding 2.7% against 2.1% (P=0.06)3 |
| Nicholls and colleagues, STRENGTH, JAMA 20204 | Double-blind, randomized, multicenter; stopped early; funded by AstraZeneca4 | 13 078 statin-treated patients at high cardiovascular risk with hypertriglyceridemia and low HDL cholesterol, 70% with diabetes4 | Omega-3 carboxylic acids 4 g/d or corn oil; median treatment more than 3 years4 | Primary composite in 785 (12.0%) against 795 (12.2%) (hazard ratio 0.99, 95% CI 0.90-1.09; P = .84); gastrointestinal adverse events 24.7% against 14.7%4 |
| Manson and colleagues, VITAL, New England Journal of Medicine 20195 | Double-blind, placebo-controlled, 2×2 factorial with vitamin D3; funded by the National Institutes of Health and others5 | 25,871 men aged 50 or older and women aged 55 or older in a primary prevention setting, including 5,106 African Americans5 | Fish oil capsule 1 g/day (840 mg n-3: EPA 460 mg, DHA 380 mg) or placebo; median 5.3 years5 | Major cardiovascular events 386 against 419 (hazard ratio 0.92, 95% CI 0.80-1.06; p=0.24); invasive cancer hazard ratio 1.03 (0.93-1.13); prespecified secondary outcomes: total myocardial infarction hazard ratio 0.72 (0.59-0.90), total stroke 1.04 (0.83-1.31), cardiovascular mortality 0.96 (0.76-1.21); no excess risks of bleeding or other serious adverse events5 |
| ASCEND Study Collaborative Group, New England Journal of Medicine 20186 | Randomized, multicenter, olive oil placebo; funded by the British Heart Foundation and others6 | 15,480 patients with diabetes and no evidence of atherosclerotic cardiovascular disease6 | 1 g capsule of n-3 fatty acids daily or placebo; mean follow-up 7.4 years (adherence rate 76%)6 | Serious vascular event in 689 (8.9%) against 712 (9.2%) (rate ratio 0.97, 95% CI 0.87 to 1.08; P=0.55); death from any cause 9.7% against 10.2%; no significant between-group differences in nonfatal serious adverse events6 |
| Gencer and colleagues, Circulation 20219 | Systematic review and meta-analysis of randomized trials with at least 500 patients and a median follow-up of at least one year9 | 81,210 patients in 7 trials9 | Marine omega-3 supplements; 72.6% of patients in trials testing 1 g/d or less9 | Atrial fibrillation hazard ratio 1.25 (95% CI 1.07–1.46); 1.49 (1.04–2.15) in trials testing above 1 g/d and 1.12 (1.03–1.22) at 1 g/d or less9 |
| Abdelhamid and colleagues, Cochrane Database of Systematic Reviews 202010 | Systematic review and meta-analysis of randomized trials lasting at least 12 months10 | 86 trials, 162,796 adults at varying cardiovascular risk10 | Long-chain omega-3 doses from 0.5 g a day to more than 5 g a day; trials of 12 to 88 months10 | All-cause mortality risk ratio 0.97 (95% CI 0.93 to 1.01); cardiovascular mortality 0.92 (0.86 to 0.99, moderate-certainty); cardiovascular events 0.96 (0.92 to 1.01); stroke 1.02 (0.94 to 1.12, moderate-certainty); coronary heart disease events 0.91 (0.85 to 0.97, low-certainty)10 |
| Lovaza label, two placebo-controlled trials2 | Randomized, placebo-controlled, double-blind, parallel-group2 | 84 adults with baseline triglycerides of 500 to 2,000 mg/dL2 | Lovaza 4 grams per day or placebo; 6 and 16 weeks2 | Median triglycerides, VLDL-C and non-HDL-C reduced and HDL-C increased relative to placebo; elevations in LDL-C and non-HDL-C possible in some individuals2 |
Deeper analysis: REDUCE-IT
Bhatt and colleagues reported REDUCE-IT in the New England Journal of Medicine in 2019, and the first author lists the Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston.3 The trial enrolled statin-treated patients with a fasting triglyceride level of 135 to 499 mg per deciliter and an LDL cholesterol level of 41 to 100 mg per deciliter, who had established cardiovascular disease or diabetes with other risk factors.3 The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina; the key secondary end point was cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.3 The key secondary end point rates were 11.2% and 14.8% (hazard ratio 0.74, 95% CI 0.65 to 0.83), and cardiovascular death was 4.3% against 5.2% (hazard ratio 0.80, 95% CI 0.66 to 0.98; P=0.03).3 The journal states "Funded by Amarin Pharma", and the affiliation list places five authors (S.B.K., R.T.D.J., R.A.J., L.J. and C.G.) at Amarin Pharma, Bedminster, NJ.3 The registry entry names Amarin Pharma Inc. as lead sponsor (class industry) and lists 274 deaths among 4089 participants in the icosapent ethyl (AMR101) group and 310 among 4090 on placebo, with serious adverse events in 1252 and 1254.11 The STRENGTH authors discuss that the REDUCE-IT comparator was mineral oil, "with adverse effects, compared with baseline, on apolipoprotein B, LDL cholesterol, and hs-CRP levels", and add that the FDA's label claim rested on analyses concluding that the mineral oil effects "could not entirely explain the observed differences in outcome".4 The limitations the REDUCE-IT authors state in the full text are not reported here, because only the journal summary text was read.
Deeper analysis: STRENGTH
Nicholls and colleagues reported STRENGTH in JAMA in 2020: a double-blind, randomized, multicenter trial at 675 hospitals in 22 countries comparing 4 g/d of an omega-3 carboxylic acid formulation of EPA and DHA with corn oil, added to usual background therapies including statins.4 The mean age was 62.5 years, 35% were women, 70% had diabetes, and median triglycerides were 240 mg/dL.4 The trial was halted when 1384 patients had had a primary end point event of a planned 1600, "based on an interim analysis that indicated a low probability of clinical benefit", and 12 633 (96.6%) completed with ascertainment of primary end point status.4 The primary end point occurred in 785 patients (12.0%) on omega-3 carboxylic acids and 795 (12.2%) on corn oil (hazard ratio 0.99, 95% CI 0.90-1.09; P = .84).4 Gastrointestinal adverse events were more frequent with omega-3 carboxylic acids (24.7%) than with corn oil (14.7%), and the authors report a greater rate of study drug discontinuation and more investigator-reported new-onset atrial fibrillation, with no excess bleeding.4 The authors name three limitations: all patients were at high risk with background statin therapy required, a fixed 4 g/d EPA and DHA combination was tested, and "no large clinical trial has evaluated the effect of purified DHA at any dose on cardiovascular outcomes".4 They also write that "there is some uncertainty whether there is net benefit or harm with administration of any omega-3 fatty acid formulation".4 The trial was funded by AstraZeneca AB and coordinated by the Cleveland Clinic Coordinating Center for Clinical Research, and the sponsor "participated actively in designing the study in collaboration with the steering committee".4 The disclosures state that sponsor employees are coauthors who "provided review of the drafts", that Dr Davidson was founder and chief medical officer of Omthera Pharmaceuticals, which developed Epanova and was acquired by AstraZeneca in 2013, then an AstraZeneca employee from 2013 to 2015, and that Dr Katona and Dr Himmelmann reported owning AstraZeneca shares.4 The same statement adds that Dr Davidson has served on the STRENGTH steering committee since 2015 with a $10 000 yearly honorarium, that Dr Loss reported owning stock in AstraZeneca, and that the sponsor maintained the trial database, with a copy transferred to the coordinating center, where an independent statistician performed the analyses.4
Deeper analysis: VITAL
Manson and colleagues reported VITAL in the New England Journal of Medicine in 2019, a randomized, double-blind, placebo-controlled, 2×2 factorial trial of vitamin D3 (2000 IU/day) and marine omega-3 fatty acids (1 g/day) in 25,871 US adults, including 5,106 African Americans, with the omega-3 results reported in this paper.5 Among 1,583 participants with a one-year blood sample, the mean omega-3 index rose from a baseline of 2.67% to 4.13% (a 54.7% increase) in the active group.5 The primary end points did not differ: 805 major cardiovascular events (hazard ratio 0.92, 95% CI 0.80-1.06; p=0.24) and 1,617 invasive cancers (hazard ratio 1.03, 95% CI 0.93-1.13).5 Among secondary outcomes, total myocardial infarction had a hazard ratio of 0.72 (0.59-0.90), while total stroke was 1.04 (0.83-1.31), cardiovascular mortality 0.96 (0.76-1.21) and all-cause mortality 1.02 (0.90-1.15).5 The paper reports no significant differences in gastrointestinal symptoms, major bleeding episodes or other serious side effects compared with placebo.5 The authors state that "the trial's single n-3 dose did not permit exploration of dose-response relationships" and that median treatment duration was 5.3 years.5 The paper also states that there was no control for multiple hypothesis testing, with no formal adjustment to the p-values or confidence intervals, and that some subgroup analyses are based on small numbers of events.5 VITAL was supported by National Institutes of Health institutes, and Pronova BioPharma of Norway and BASF donated the Omacor fish oil study agents, matching placebos and packaging; the conflict of interest statement says all authors submitted ICMJE disclosure forms, which the text read does not itemize.5
Deeper analysis: ASCEND and the atrial fibrillation meta-analysis
The ASCEND Study Collaborative Group reported in the New England Journal of Medicine in 2018 that, among 15,480 patients with diabetes, a serious vascular event occurred in 689 (8.9%) on 1 g n-3 capsules and 712 (9.2%) on olive oil placebo (rate ratio 0.97, 95% CI 0.87 to 1.08; P=0.55), with the composite including revascularization at 11.4% against 11.5%.6 Funding was from the British Heart Foundation and others, with Medical Research Council grants listed; the authors' own limitations are not reported here because only the journal summary text was read.6 Gencer and colleagues pooled 7 trials of marine omega-3 supplements and reported an increased atrial fibrillation risk (hazard ratio 1.25, 95% CI 1.07–1.46, P=0.013), larger in trials testing above 1 g/d (1.49, 1.04–2.15) than at 1 g/d or less (1.12, 1.03–1.22).9 Their stated limitations include that "differences exist in the AF outcome assessment between trials", and that not every large trial reported AF outcomes.9
Doses reported in studies and on labels
The app lists a typical dose of 2 to 4 g/day by mouth; the rows below give the products, doses, comparators and group sizes the sources report.
| Source | Product, dose and route | People, comparator and length |
|---|---|---|
| Vascepa label1 | Icosapent ethyl, 4 grams per day by mouth as four 0.5 gram capsules twice daily with food or two 1 gram capsules twice daily with food1 | Adults within the label indications; no comparator on the label dosing line1 |
| Lovaza label2 | Omega-3-acid ethyl esters, 4 grams per day by mouth, as a single 4-gram dose (4 capsules) or two 2-gram doses (2 capsules given twice daily)2 | Adults with severe hypertriglyceridemia; trials of 4 g/day against placebo in 84 adults for 6 and 16 weeks2 |
| REDUCE-IT3 | Icosapent ethyl 2 g twice daily (4 g/day) by mouth3 | 8179 patients against placebo; median 4.9 years3 |
| STRENGTH4 | Omega-3 carboxylic acids 4 g/d4 | 13 078 patients against corn oil; median treatment more than 3 years4 |
| VITAL5 | Fish oil capsule 1 g/day containing 840 mg n-3 fatty acids (EPA 460 mg, DHA 380 mg)5 | 25,871 adults against placebo; median 5.3 years5 |
| ASCEND6 | 1-g capsules of n-3 fatty acids daily6 | 15,480 patients with diabetes against olive oil placebo; mean follow-up 7.4 years6 |
| Plourde 20148 | Supplement providing 1.4 g DHA plus 1.8 g EPA per day for 5 months8 | 34 healthy adults aged 52 to 90, baseline kinetic study as comparator8 |
Side effects reported
The Vascepa label lists as common adverse reactions in its cardiovascular outcomes trial (incidence 3% or more on Vascepa and at least 1% more frequent than placebo) musculoskeletal pain, peripheral edema, constipation, gout and atrial fibrillation.1 For its two 12-week placebo-controlled trials in patients with triglyceride levels between 200 and 2000 mg/dL, the label lists arthralgia and oropharyngeal pain at an incidence of at least 1% more frequent than placebo.1 The label warns that Vascepa "was associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization" and that the incidence was greater in patients with a previous history of atrial fibrillation or flutter.1 It also lists an increased risk of bleeding, greater in patients on concomitant antithrombotic medications such as aspirin, clopidogrel or warfarin.1 The Vascepa label also states that it is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to Vascepa.1 The Lovaza label, pooling 23 clinical trials, lists eructation, dyspepsia and taste perversion as the most common adverse reactions, at more than 3% and above placebo.2 The Lovaza label notes a possible association with more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of therapy.2 Both labels say some studies or trials of omega-3 fatty acids showed prolonged bleeding time, and both state that the prolongation "has not exceeded normal limits and did not produce clinically significant bleeding episodes".1,2 The outcome trials' own adverse event findings are in the study sections above: more gastrointestinal events and atrial fibrillation in STRENGTH, more atrial fibrillation or flutter hospitalization in REDUCE-IT, no excess risks of bleeding or other serious adverse events in VITAL, and no significant between-group differences in the rates of nonfatal serious adverse events in ASCEND.4,3,5,6
Bloodwork and markers
The app lists no health markers to monitor for omega-3 fish oil. Triglycerides fell in the label trials: Vascepa 4 grams per day reduced median TG, VLDL-C and Apo B relative to placebo without elevations in LDL-C, while Lovaza 4 grams per day reduced median TG, VLDL-C and non-HDL-C and raised HDL-C.1,2 The Cochrane review reported that increasing long-chain omega-3 reduced triglycerides by about 15% in a dose-dependent way (high-certainty evidence).10 The Lovaza label says LDL-C levels may increase in some patients and calls for periodic LDL-C monitoring during therapy, that ALT, without a concurrent AST rise, increased in some patients, and that in patients with hepatic impairment ALT and AST levels are monitored periodically during therapy.2 In VITAL, the mean plasma omega-3 index (EPA plus DHA as a percent of total fatty acids) rose to 4.13% in the 1 g/day group, from a baseline mean of 2.67%.5
Regulatory and anti-doping status
Sources in this part
The Vascepa label gives 2012 as its initial US approval year and the Lovaza label gives 2004.1,2 The Vascepa label carries a limitation of use: the effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.1 A text search of the WADA 2026 Prohibited List for "omega", "fish oil", "eicosapentaenoic" and "docosahexaenoic" returned no match.12
Storage and handling
Sources in this part
What is not known
STRENGTH's authors state that whether benefits might be seen in a lower-risk primary prevention population "remains uncertain", in a trial where all patients were at high cardiovascular risk.4 The Vascepa label says the direct clinical meaning of individual mechanism findings is not clear, and the Lovaza label says its mechanism of action is not completely understood.1,2 The app's 95% bioavailability has no matching figure in the two labels read, and the app's one-compartment model sits beside a bi-exponential washout seen in 3 of 5 volunteers for triacylglycerol fractions.1,7 Whether the half-life and trial results above carry across to a retail fish oil supplement at 2 to 4 g/day is not addressed by these sources, which cover prescription products, a 1 g capsule in VITAL and ASCEND, and single small kinetic studies.5,6,7,8
Frequently asked questions
What is the half-life of omega-3 fish oil?
The Vascepa label gives the plasma elimination half-life of EPA as approximately 89 hours, and the app lists 48 hours.1 A study of 5 healthy volunteers reported a mean EPA half-life in plasma phospholipids of 1.97 days.7 A study of 34 older adults reported a plasma labelled-DHA half-life of 4.5 days at baseline and 3.0 days on a supplement.8
How long does omega-3 take to reach its peak level?
What is the bioavailability of omega-3 fish oil?
Is omega-3 fish oil banned by WADA?
A text search of the WADA 2026 Prohibited List for "omega", "fish oil", "eicosapentaenoic" and "docosahexaenoic" returned no match.12
Did omega-3 fish oil reduce heart attacks and strokes in trials?
Trial results differ: REDUCE-IT reported a lower rate of its primary composite on icosapent ethyl (17.2% against 22.0%), while STRENGTH (12.0% against 12.2%) and ASCEND (8.9% against 9.2%) found no significant difference.3,4,6 VITAL reported no significant difference in major cardiovascular events (hazard ratio 0.92, 95% CI 0.80-1.06) and a Cochrane review of 86 trials found little or no effect on cardiovascular events (risk ratio 0.96, 95% CI 0.92 to 1.01).5,10
Does omega-3 fish oil raise the risk of atrial fibrillation?
A meta-analysis of 7 trials reported a hazard ratio of 1.25 (95% CI 1.07–1.46) for atrial fibrillation with marine omega-3 supplements.9 REDUCE-IT reported hospitalization for atrial fibrillation or flutter in 3.1% on icosapent ethyl against 2.1% on placebo, and the Cochrane review's arrhythmia risk ratio was 0.99 (95% CI 0.92 to 1.06; low-certainty evidence).3,10
Does omega-3 fish oil lower triglycerides?
The Cochrane review reported that increasing long-chain omega-3 reduced triglycerides by about 15% in a dose-dependent way (high-certainty evidence).10 The Lovaza and Vascepa labels report reductions in median triglycerides at 4 grams per day relative to placebo, and the Lovaza label adds that LDL-C and non-HDL-C may rise in some individuals.2,1
Guides, tools and comparisons
References
- Amarin Pharma. Vascepa (icosapent ethyl) capsules. US prescribing information, DailyMed record version 21, 2026. Vascepa label
- Waylis Therapeutics. Lovaza (omega-3-acid ethyl esters) capsules. US prescribing information, DailyMed record version 4, 2026. Lovaza label
- Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019. PMID 30415628
- Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020. PMID 33190147
- Manson JE, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2019. PMID 30415637
- ASCEND Study Collaborative Group, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 2018. PMID 30146932
- Zuijdgeest-van Leeuwen SD, et al. Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions. Br J Nutr 1999. PMID 10690163
- Plourde M, et al. Kinetics of 13C-DHA before and during fish-oil supplementation in healthy older individuals. Am J Clin Nutr 2014. PMID 24829492
- Gencer B, et al. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation 2021. PMID 34612056
- Abdelhamid AS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020. PMID 32114706
- Amarin Pharma Inc. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin. ClinicalTrials.gov NCT01492361. NCT01492361
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list